Drug intelligence / Profile preview

R-IDARAM

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Intrathecal

Overview

R-IDARAM is a combination chemotherapy regimen used for the treatment of central nervous system lymphomas (CNSLs), including primary and secondary CNS lymphomas. It consists of rituximab, idarubicin, dexamethasone, cytarabine, and methotrexate, often combined with intrathecal administration of chemotherapeutic agents. The regimen has shown high early response rates with manageable toxicity, with hematological side effects being the main concern.

Other names: R-IDARAM regimen

Targets

CD20 (B-lymphocyte antigen CD20)DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA

Beyond the preview

Go deeper on R-IDARAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-IDARAM.

Explore the full profile